Snail: a target for treating basal-like breast cancer
Screening mammography in older women: the balance between appropriate use and overuse
New possible target found that could reduce breast cancer metastasis
Potential dual function for breast cancer enzyme
Reducing the risk of breast cancer through aerobics
Uncertainty over the benefits of diabetes drug in breast cancer patients
Can we modulate miRNAs for breast cancer treatment?
Allevi G, Strina C, Andreis D et al. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. Br. J. Cancer 108(8), 1587–1592 (2013).
Rimawi MF, Mayer IA, Forero A et al. Multicenter Phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J. Clin. Oncol. 31(14), 1726–1731 (2013).
Makhoul I, Klimberg VS, Korourian S et al. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer. Am. J. Clin. Oncol. doi:10.1097/COC.0b013e31828940c3 (2013) (Epub ahead of print).
Gianni L, Romieu GH, Lichinitser M et al. AVEREL: a randomized Phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J. Clin. Oncol. 31(14), 1719–1725 (2013).
Interview: Breast cancer clinical trials: current issues and possible solutions
Conference Scene: Update from the 30th Miami Breast Cancer Conference
Mimicking pregnancy as a strategy for breast cancer prevention
Detection and prognostic significance of circulating tumor cells in nonmetastatic breast cancer patients
Inflammation and breast cancer
Adjuvant bisphosphonates in breast cancer: has the time come?
Can eribulin change the treatment algorithm in the management of breast cancer?